{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T01:54:14Z","timestamp":1791942854136,"version":"4.3.4"},"reference-count":30,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T00:00:00Z","timestamp":1696204800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005646","name":"Actelion Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005646","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jhltonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Heart and Lung Transplantation"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.healun.2023.09.016","type":"journal-article","created":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T12:19:06Z","timestamp":1695989946000},"page":"272-283","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Disease characteristics, treatments, and outcomes of patients with pulmonary arterial hypertension treated with selexipag in real-world settings from the SPHERE registry (SelexiPag: tHe usErs dRug rEgistry)"],"prefix":"10.1016","volume":"43","author":[{"given":"Vallerie","family":"McLaughlin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harrison W.","family":"Farber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin B.","family":"Highland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna R.","family":"Hemnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murali M.","family":"Chakinala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly M.","family":"Chin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9753-7768","authenticated-orcid":false,"given":"Michelle","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7334-2915","authenticated-orcid":false,"given":"Tobore","family":"Tobore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick H.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.healun.2023.09.016_bib1","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","article-title":"2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"43","author":"Humbert","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.healun.2023.09.016_bib2","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1164\/rccm.200510-1668OC","article-title":"Pulmonary arterial hypertension in France: results from a national registry","volume":"173","author":"Humbert","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.healun.2023.09.016_bib3","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1161\/CIRCULATIONAHA.109.911818","article-title":"Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era","volume":"122","author":"Humbert","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.healun.2023.09.016_bib4","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1183\/09031936.00072709","article-title":"Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation","volume":"35","author":"Thenappan","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1016\/j.healun.2023.09.016_bib5","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1136\/annrheumdis-2012-202489","article-title":"Survival in systemic sclerosis-associated pulmonary arterial hypertension in the modern management era","volume":"72","author":"Launay","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.healun.2023.09.016_bib6","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1164\/rccm.202009-3698OC","article-title":"Association between initial treatment strategy and long-term survival in pulmonary arterial hypertension","volume":"204","author":"Boucly","year":"2021","journal-title":"Am J Crit Care Med"},{"key":"10.1016\/j.healun.2023.09.016_bib7","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.chest.2018.11.030","article-title":"Therapy for pulmonary arterial hypertension in adults. Update of the CHEST guideline and expert panel report","volume":"155","author":"Klinger","year":"2019","journal-title":"Chest"},{"key":"10.1016\/j.healun.2023.09.016_bib8","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1056\/NEJMoa1503184","article-title":"Selexipag for the treatment of pulmonary arterial hypertension","volume":"373","author":"Sitbon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.healun.2023.09.016_bib9","first-page":"49","article-title":"The value of pragmatic and observational studies in health care and public health","volume":"8","author":"Barnish","year":"2017","journal-title":"Pragmat Obs Res"},{"key":"10.1016\/j.healun.2023.09.016_bib10","unstructured":"Food and Drug AdministrationStatement from FDA Commissioner Scott Gottlieb, M.D., on FDA\u2019s new strategic framework to advance use of real-world evidence to support development of drugs and biologics. December 2018. Available at: \u3008https:\/\/www.fda.gov\/news-events\/press-announcements\/statement-fda-commissioner-scott-gottlieb-md-fdas-new-strategic-framework-advance-use-real-world\u3009. Accessed January 2, 2023."},{"key":"10.1016\/j.healun.2023.09.016_bib11","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s12325-018-0805-y","article-title":"Interpretation and impact of real-world clinical data for the practicing clinician","volume":"35","author":"Blonde","year":"2018","journal-title":"Adv Ther"},{"key":"10.1016\/j.healun.2023.09.016_bib12","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0050-2019","article-title":"Learning from registries in pulmonary arterial hypertension: pitfalls and recommendations","volume":"28","author":"Swinnen","year":"2019","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.healun.2023.09.016_bib13","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.healun.2021.01.006","article-title":"Patient and disease characteristics of the first 500 patients with pulmonary arterial hypertension treated with selexipag in real-world settings from SPHERE","volume":"40","author":"Kim","year":"2021","journal-title":"J Heart Lung Transpl"},{"key":"10.1016\/j.healun.2023.09.016_bib14","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.chest.2019.02.004","article-title":"Predicting survival in patients with pulmonary arterial hypertension: the REVEAL risk score calculator 2.0 and comparison with ESC\/ERS-based risk assessment strategies","volume":"156","author":"Benza","year":"2019","journal-title":"Chest"},{"key":"10.1016\/j.healun.2023.09.016_bib15","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2307\/2530286","article-title":"A confidence interval for the median survival time","volume":"38","author":"Brookmeyer","year":"1982","journal-title":"Biometrics"},{"issue":"4S","key":"10.1016\/j.healun.2023.09.016_bib16","doi-asserted-by":"crossref","first-page":"2318A","DOI":"10.1016\/j.chest.2021.07.2016","article-title":"REVEAL Lite 2 risk assessment in patients with pulmonary arterial hypertension from the GRIPHON study: a post-hoc analysis demonstrates association of risk status with long-term outcomes","volume":"160","author":"Benza","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.healun.2023.09.016_bib17","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1378\/chest.09-1140","article-title":"Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry","volume":"137","author":"Badesch","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.healun.2023.09.016_bib18","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1378\/chest.10-0075","article-title":"The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US contemporary registries","volume":"139","author":"Frost","year":"2011","journal-title":"Chest"},{"key":"10.1016\/j.healun.2023.09.016_bib19","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02024-2021","article-title":"Temporal trends in pulmonary arterial hypertension: results from the COMPERA registry","volume":"59","author":"Hoeper","year":"2022","journal-title":"Eur Respir J"},{"key":"10.1016\/j.healun.2023.09.016_bib20","unstructured":"Swedish P.A.H. & C.T.E.P.H. Registry. Annual Report 2021. Available at: \u3008https:\/\/www.ucr.uu.se\/spahr\/arsrapporter\/arsrapport-2021\/viewdocument\/155\u3009. Accessed January 2, 2023."},{"key":"10.1016\/j.healun.2023.09.016_bib21","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/j.jacc.2021.07.057","article-title":"Three- versus two-drug therapy for patients with newly diagnosed pulmonary arterial hypertension","volume":"78","author":"Chin","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.healun.2023.09.016_bib22","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1056\/NEJMoa1413687","article-title":"Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension","volume":"373","author":"Gali\u00e8","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.healun.2023.09.016_bib23","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.chest.2019.10.043","article-title":"Results of an expert consensus survey on the treatment of pulmonary arterial hypertension with oral prostacyclin pathway agents","volume":"157","author":"McLaughlin","year":"2020","journal-title":"Chest"},{"key":"10.1016\/j.healun.2023.09.016_bib24","unstructured":"NHS Digital. National Audit of Pulmonary Hypertension Great Britain, 2020\u201321, 12th Annual Report, v1.1. Available at: \u3008https:\/\/files.digital.nhs.uk\/75\/83A559\/NAPH%2012AR%20-%20Main%20Report%20v1.1.pdf\u3009. Accessed January 2, 2023."},{"key":"10.1016\/j.healun.2023.09.016_bib25","doi-asserted-by":"crossref","first-page":"731","DOI":"10.2147\/CEOR.S119117","article-title":"Early intervention in the management of pulmonary arterial hypertension: clinical and economic outcomes","volume":"9","author":"Burger","year":"2017","journal-title":"Clin Outcomes Res"},{"key":"10.1016\/j.healun.2023.09.016_bib26","doi-asserted-by":"crossref","DOI":"10.1186\/s12890-022-01906-2","article-title":"The economic burden of pulmonary arterial hypertension in Spain","volume":"22","author":"Zozaya","year":"2022","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.healun.2023.09.016_bib27","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00456-2022","article-title":"Early selexipag initiation and long-term outcomes: insights from randomised controlled trials in pulmonary arterial hypertension","volume":"9","author":"Coghlan","year":"2023","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.healun.2023.09.016_bib28","doi-asserted-by":"crossref","DOI":"10.1177\/1753466619843774","article-title":"Baseline history of patients using selexipag for pulmonary arterial hypertension","volume":"13","author":"Highland","year":"2019","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.healun.2023.09.016_bib29","unstructured":"Uptravi. Prescribing information. Actelion Pharmaceuticals US; 2022. Available at: \u3008https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/UPTRAVI-pi.pdf\u3009. Accessed January 2, 2023."},{"key":"10.1016\/j.healun.2023.09.016_bib30","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","article-title":"2015 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"37","author":"Gali\u00e8","year":"2016","journal-title":"Eur Heart J"}],"updated-by":[{"DOI":"10.1016\/j.healun.2025.04.016","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000}}],"container-title":["The Journal of Heart and Lung Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053249823020272?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053249823020272?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T15:15:04Z","timestamp":1762355704000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1053249823020272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S1053249823020272"],"URL":"https:\/\/doi.org\/10.1016\/j.healun.2023.09.016","relation":{},"ISSN":["1053-2498"],"issn-type":[{"value":"1053-2498","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Disease characteristics, treatments, and outcomes of patients with pulmonary arterial hypertension treated with selexipag in real-world settings from the SPHERE registry (SelexiPag: tHe usErs dRug rEgistry)","name":"articletitle","label":"Article Title"},{"value":"The Journal of Heart and Lung Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.healun.2023.09.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of International Society for Heart and Lung Transplantation.","name":"copyright","label":"Copyright"}]}}